Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

59 comunicati stampa

Guarda tutti i comunicati
21/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Biotecnologia
Salute
Oncologia
Web e Social Network
Agenus to Host First 2026 Stakeholder Webcast
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
15/01/2026
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Industria
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Industria
Biotecnologia
Salute
Oncologia
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Web e Social Network
Biotecnologia
Salute
Oncologia
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Mercato del lavoro
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
Oncologia
Web e Social Network
Mercato azionario
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Web e Social Network
Finanza
Mercato azionario
Biotecnologia
Salute
Oncologia
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
17/10/2025
Biotecnologia
Salute
Oncologia
Eventi
Fiere
Industria
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0